Sensei Biotherapeutics, Inc.
Data quality: 83%
SNSE
Nasdaq
Manufacturing
Chemicals
$30.70
▼
$1.01
(-3.19%)
Mkt Cap: 41.15 M
Price
$30.70
Mkt Cap
41.15 M
Day Range
$30.30 — $32.30
52-Week Range
$5.26 — $36.76
Volume
49,878
Open $31.50
50D / 200D Avg
$23.33
31.61% above
50D / 200D Avg
$12.67
142.35% above
Quick Summary
Key Takeaways
Negative free cash flow of -20.47 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-83.80%
Below sector avg (-53.41%)
ROIC-68.96%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio5.81
Interest Coverage-696.50
Valuation
PE (TTM)
-1.95
Below sector avg (-1.48)
P/B Ratio1.79
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -2.0 | -1.5 |
| P/B | 1.8 | 1.6 |
| ROE % | -83.8 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -21.09 M |
| ROE | -83.80% | ROA | -71.03% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -20.47 M |
| ROIC | -68.96% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 5.81 |
| Interest Coverage | -696.50 | Asset Turnover | N/A |
| Working Capital | 21.35 M | Tangible Book Value | 23.01 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.95 | Forward P/E | N/A |
| P/B Ratio | 1.79 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -49.75% | ||
| Market Cap | 41.15 M | Enterprise Value | 30.58 M |
| Per Share | |||
| EPS (Diluted TTM) | -16.72 | Revenue / Share | N/A |
| FCF / Share | -15.27 | OCF / Share | -15.26 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 97.08% |
| SBC-Adj. FCF | -22.18 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -21.09 M | -30.16 M | -34.10 M | -48.59 M | -36.79 M |
| EPS (Diluted) | -16.72 | -1.20 | -1.22 | -1.58 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -22.29 M | -32.61 M | -37.06 M | -50.19 M | -37.48 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | 122,000.0 | 551,000.0 | 571,000.0 | 614,000.0 | 685,000.0 |
| Interest Expense | 32,000.0 | 90,000.0 | 144,000.0 | 219,000.0 | 670,000.0 |
| Income Tax | 0.0 | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 22.90 M | 45.36 M | 74.37 M | 118.38 M | 153.23 M |
| Total Liabilities | 4.31 M | 6.98 M | 9.48 M | 14.97 M | 6.71 M |
| Shareholders' Equity | 18.59 M | 38.39 M | 64.90 M | 103.41 M | 146.51 M |
| Total Debt | — | — | — | — | 567,000.0 |
| Cash & Equivalents | 8.67 M | 9.99 M | 13.01 M | 17.80 M | 7.16 M |
| Current Assets | 21.51 M | 41.93 M | 67.25 M | 108.59 M | 148.54 M |
| Current Liabilities | 4.25 M | 5.45 M | 5.64 M | 9.07 M | 4.89 M |
{"event":"ticker_viewed","properties":{"ticker":"SNSE","listing_kind":"stock","pathname":"/stocks/snse","exchange":"Nasdaq","country":"US"}}